TY - JOUR
AU1 - Deshotels, Matthew R.
AU2 - Virani, Salim S.
AU3 - Ballantyne, Christie M.
AB - Purpose of ReviewThe 2015 American College of Cardiology (ACC)/American Heart Association (AHA) Focused Update of Secondary Prevention Lipid Performance Measures removed low-density lipoprotein cholesterol (LDL-C) assessment as a performance measure. This review discusses the evidence supporting the importance of lipid monitoring in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD).Recent FindingsThe 2018 AHA/ACC Multisociety cholesterol guideline (as did the 2013 guideline) recommends a lipid panel after initiating lipid-lowering therapy to monitor adherence and medication efficacy. The 2018 guideline also recommends adding nonstatin therapy in very-high-risk ASCVD patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy.SummaryThe removal of LDL-C monitoring as a performance measure is not consistent with the 2018 cholesterol guidelines. Given the importance of monitoring lipid-lowering medication efficacy and adherence and optimally reducing LDL-C in very-high-risk patients with additional evidence-based nonstatin therapy, LDL-C assessment after initiating lipid-lowering therapy should be reinstated as a performance measure for patients with ASCVD.
TI - Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?
JF - Current Cardiology Reports
DO - 10.1007/s11886-021-01545-9
DA - 2021-07-16
UR - https://www.deepdyve.com/lp/springer-journals/lipid-monitoring-after-initiation-of-lipid-lowering-therapies-return-gjJDQdxh3g
VL - 23
IS - 9
DP - DeepDyve
ER -